ArticleOncoTargets and therapy2018
CXCR3 is a prognostic marker and a potential target for patients with solid tumors: a meta-analysis.
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- CXCR3 gene as a therapeutic target in colorectal cancer.BMC cancer · 2025Article
- Metabolic insights into tumor lymph node metastasis in melanoma.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- CXCR3 predicts the prognosis of endometrial adenocarcinoma.BMC medical genomics · 2023Article
- Multifaceted role of chemokines in solid tumors: From biology to therapy.Seminars in cancer biology · 2022Review
- Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician.Cancers · 2021Review
- Role of the CXCR3‑mediated TLRs/MyD88 signaling pathway in promoting the development of hepatitis B into cirrhosis and liver cancer.Molecular medicine reports · 2021Article
- CXCL11 Correlates With Antitumor Immunity and an Improved Prognosis in Colon Cancer.Frontiers in cell and developmental biology · 2021Article
- The Expression of Selected Factors Related to T Lymphocyte Activity in Canine Mammary Tumors.International journal of molecular sciences · 2020Article
- Immune Cluster and PPI Network Analyses Identified CXCR3 as a Key Node of Immunoregulation in Head and Neck Cancer.Frontiers in oncology · 2020Article
- The Chemokine Receptor CXCR3 Isoform B Drives Breast Cancer Stem Cells.Breast cancer : basic and clinical research · 2019Article
- The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo deeply verify the clinical significance of CXCR3 in prediction of cancer patients' prognosis. DATA SOURCES: We performed a meta-analysis including 12 studies searched from PubMed, Web of Science, Embase, and Cochrane databases. A total of 1,751 patients were used to analyze the association between CXCR3 and patients' prognosis, based on either overall survival or time to tumor progression. STUDY SELECTION: Studies evaluating CXCR3 expression for predicting prognosis in human solid tumors were included.
resultsIt showed that patients with higher expression of CXCR3 had significantly shorter OS (pooled hazard ratio =2.315, 95% CI: 1.162-4.611,
conclusionOur study highlights the role of CXCR3 as a potential prognostic marker and a promising therapeutic target in solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.